Intensity-Modulated Radiation Therapy May Prove Better than Other Radiation Techniques for Prostate Cancer (04-26-2012)

In an analysis of three different types of radiation therapy used to treat localized prostate cancer, intensity-modulated radiation therapy (IMRT) was associated with fewer gastrointestinal side effects and fewer hip fractures, but more erectile dysfunction... Continue Reading

Less Invasive Prostate Removal Safer than Traditional Surgery (04-24-2012)

Minimally-invasive radical prostatectomy (MIRP) proves safer than traditional open surgery—resulting in fewer post-surgical complications, fewer blood transfusions, and shorter hospital stays, according to the results of a study published in European... Continue Reading

NIH Panel Supports Active Surveillance as Option for Low-Risk Prostate Cancer (02-23-2012)

According to the conclusions of a National Institutes of Health (NIH) State-of-the-Science Conference, active surveillance is a viable option for the management of low-risk prostate cancer. Prostate cancer is the most commonly diagnosed cancer (other... Continue Reading

Drug May Delay Need for Prostate Cancer Treatment (01-26-2012)

Among men who choose active surveillance for early-stage prostate cancer, Avodart® (dutasteride) may delay cancer progression and the need for cancer treatment. These results were published in The Lancet. The management of early prostate cancer may involve... Continue Reading

Robotic Surgery May Not Reduce Common Prostatectomy Side Effects (01-11-2012)

Among men who undergo radical prostatectomy for the treatment of early-stage prostate cancer, robotic-assisted laparoscopic surgery may not result in better urinary or sexual function than traditional, open surgery. These results were published in the... Continue Reading

Shorter Course of Radiation Therapy Appears to be Effective for Prostate Cancer (10-11-2011)

Delivering a shorter course of external-beam radiation therapy—with higher doses of radiation given at each visit—appears to be as effective for prostate cancer as the conventional approach to external-beam radiation therapy. These results were presented... Continue Reading

Xgeva Delays Onset of Bone Metastases (09-27-2011)

Among men with prostate cancer that has stopped responding to hormonal therapy, the bone drug Xgeva™ (denosumab) delayed the spread of cancer to the bones. These results were presented at the 2011 European Multidisciplinary Cancer Conference. Androgen... Continue Reading

Predicting Sexual Outcomes After Prostate Cancer Treatment (09-23-2011)

Information about a man’s baseline characteristics and prostate cancer treatment plan can help predict erectile function after treatment. These results were published in the Journal of the American Medical Association. Prostate cancer is the most commonly... Continue Reading

Prolia Approved for Treatment of Bone Loss in Patients with Breast or Prostate Cancer (09-21-2011)

The U.S. Food and Drug Administration (FDA) has expanded the approval of Prolia® (denosumab) to include treatment of bone loss among breast cancer patients treated with aromatase inhibitor therapy and prostate cancer patients treated with androgen deprivation... Continue Reading

Some Prostate Cancer Patients Expect Better Recovery (08-23-2011)

Some men who undergo surgery for prostate cancer expect better recovery of sexual and urinary functions than they actually experience. These findings were recently published in the Journal of Urology. For men who undergo radical prostatectomy (complete... Continue Reading